Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

By afschroeder • August 21, 2026

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer. Gynecol Oncol Rep. 2026 Aug 12;66:102183. doi: 10.1016/j.gore.2026.102183. PMID: 42621866; PMCID: PMC13487597.

Tags: Antibody-drug conjugates, DOM STAT, Endometrial cancer, Fellow, General Internal Medicine, Hematology/Oncology, Hospitalist, ovarian cancer, Publications, real-world outcomes, trastuzumab deruxtecan

Eosinophilic cholangitis as an indeterminate biliary mimic: A systematic review of outcomes

Stirrat T, Wilkey M, Ransibrahmanakul V, Singh L, Allen O, Kanth P, Rangnekar A, Redfield R. Eosinophilic cholangitis as an indeterminate biliary mimic: A systematic[...]

Beyond Glycemia: Entering the Era of Hard Outcomes for Continuous Glucose Monitoring

Alkabbani W, Cromer SJ, Patorno E. Beyond Glycemia: Entering the Era of Hard Outcomes for Continuous Glucose Monitoring. Diabetes Care. 2026 Sep 1;49(9):1554-1556. doi: 10.2337/dci26-0084.[...]

PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study

Jafarvand M, Farolfi A, Mei R, Djaileb L, Benz M, Chung A, Brisbane W, Marks L, Grogan T, Gafita A, Theus L, Nguyen AT, Czernin[...]